The Role of Breath Testing in Enriching the Likelihood of Response to Rifaximin in Patients With Diarrhea IBS

Who is this study for? Adult patients with ulcerative colitis
What treatments are being studied? Rifaximin
Status: Recruiting
Location: See location...
Intervention Type: Device, Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

The purpose of this study is to learn more about how to improve treatment of patients with diarrhea predominant Irritable Bowel Syndrome (IBS-D) symptoms.Included patients will be requested to answer online surveys and will undergo treatment with rifaximin. Hydrogen breath testing and biologic samples collection will also be completed during the study.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: No
View:

• IBS-D (Rome IV Diagnostic Criteria)

• Diary compliance for at least 5 days and no rescue medications during baseline

• Appropriate levels of abdominal pain and diarrhea

Locations
United States
Michigan
University of Michigan
Recruiting
Ann Arbor
Contact Information
Primary
Borko Nojkov, MD
bnojkov@med.umich.edu
734-936-9455
Backup
William Chey, M.D.
wchey@med.umich.edu
734-936-4775
Time Frame
Start Date: January 9, 2020
Estimated Completion Date: January 1, 2023
Participants
Target number of participants: 110
Treatments
Experimental: Rifaximin and breath tests
Rifaximin 550mg three times a day for 14 days. Breath tests (glucose and lactulose) will be completed prior to Rifaximin treatment and at week 13 of the study.
Sponsors
Leads: University of Michigan
Collaborators: Commonwealth Diagnostics International, Inc.

This content was sourced from clinicaltrials.gov

Similar Clinical Trials